TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

1. Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
   Article
2. Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.MedComm · 2024
   Article
3. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.Journal of cancer research and clinical oncology · 2023
   Article
4. Mutations and expressions of breast cancer 1/2 in lung cancer.Thoracic cancer · 2023
   Article
5. Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor inJournal of thoracic disease · 2023
   Article
6. Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities.Nature communications · 2023
   Article
7. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.Current oncology (Toronto, Ont.) · 2022
   Article
8. Metastatic pulmonary carcinoids withTranslational lung cancer research · 2022
   Article
9. Clinicopathologic characteristics and diagnostic methods ofTranslational lung cancer research · 2022
   Article
10. Development and validation of a mFrontiers in oncology · 2022
    Article
11. Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.Journal of clinical medicine · 2019
    Article

Corrections and comments

• Comment on
  Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.2018

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as